on a psychosis caused by application of a transdermal scopolamine patch for over 15 days, in the literature there is no mention of a case in which scopolamine had such an influence nor are any cases reported in which paranoid-hallucinatory symptoms cortinued 11 days after removing the patch. ...
A scopolamine-containing transdermal therapeutic system in the form of a patch is described whose active substance-containing layers comprise as base polymer copolymers of acrylic acid or methacrylic acid derivatives and scopolamine base in a concentration corresponding to 50-100% of the saturation ...
The number of commercially available transdermal drug products has increased significantly since the initial scopolamine patch first entered the marketplace in 1980. Most of these patches deliver the drug payload by a passive diffusion mechanism, meaning only relatively small compounds with a Log P ...
Successful determination of scopolamine levels in circulating blood levels of patients administered the transdermal patch, both full and cut in half was achieved. It was found cutting the patch significantly impacted on the anticipated pharmacokinetics of the drug.Deirdre Fox...
However, variables like urea, nitrogen, DSW, ALT, lactulose, pantoprazole, pantoprazole sodium, PT, 18 gauge, bicarbonate, and creatinine were ranked higher in our method (highlighted by the red box in Figure 6), while variables like morphine sulfate, scopolamine patch, extubation, potassium ...